
The U.S. Food and Drug Administration (FDA) Approves Epcoritamab-bysp for Relapsed/Refractory Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) Approves Epcoritamab-bysp for Follicular Lymphoma Indications November 18, 2025 – On November 18, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and…








